Dr. Slapak is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
The Wishard Hospital Hematology Clinic
1050 Wishard Blvd
Indianapolis, IN 46202Phone+1 317-630-7175Fax+1 317-630-6310
Education & Training
Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1987 - 1991
University of ChicagoResidency, Internal Medicine, 1984 - 1987
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1984
Certifications & Licensure
IN State Medical License 1996 - 2025
IL State Medical License 1986 - 1987- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 75 citationsExpression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells.Christopher A. Slapak, Nobuyuki Mizunuma, Donald Kufe
Blood. 1994-11-01 - 406 citationsClinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathwayStephan Herbertz, J. Scott Sawyer, Anja Stauber, Ivelina Gueorguieva, Kyla Driscoll
Drug Design, Development and Therapy. 2015-08-10 - 41 citationsEnergy-dependent accumulation of daunorubicin into subcellular compartments of human leukemia cells and cytoplasts.Christopher A. Slapak, J M Lecerf, J C Daniel, Stuart B. Levy
The Journal of Biological Chemistry. 1992-05-25
Press Mentions
PureTech Founded Entity Vor Announces FDA Clearance of IND Application for VOR33January 14th, 2021- Vor Announces FDA Clearance of IND Application for VOR33January 14th, 2021
- Vor Biopharma Announces Exclusive License of Clinical-Stage CD33 CAR-T from National Cancer InstituteNovember 11th, 2020
- Join now to see all
Grant Support
- Anthracycline Efflux In Multiresistant Leukemia CellsNational Cancer Institute1991–1995
- Anthracycline Efflux In Multiresistant Leukemia CellsNational Cancer Institute1991
- Early Doxorubicin Resistant Mammalian Leukemia CellsNational Cancer Institute1989–1990
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
